Development
Dyne Therapeutics, Inc.
DYN
$10.47
$0.222.15%
NASDAQ
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 8.84M | 7.02M | 7.61M | 7.93M | 6.96M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 67.69M | 62.27M | 66.74M | 45.46M | 40.15M |
| Operating Income | -67.69M | -62.27M | -66.74M | -45.46M | -40.15M |
| Income Before Tax | -66.64M | -60.21M | -64.90M | -44.19M | -38.83M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -66.64M | -60.21M | -64.90M | -44.19M | -38.83M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -66.64M | -60.21M | -64.90M | -44.19M | -38.83M |
| EBIT | -67.69M | -62.27M | -66.74M | -45.46M | -40.15M |
| EBITDA | -67.29M | -61.84M | -66.31M | -45.05M | -39.74M |
| EPS Basic | -1.09 | -0.99 | -1.08 | -0.78 | -0.74 |
| Normalized Basic EPS | -0.68 | -0.62 | -0.68 | -0.49 | -0.46 |
| EPS Diluted | -1.09 | -0.99 | -1.08 | -0.78 | -0.74 |
| Normalized Diluted EPS | -0.68 | -0.62 | -0.68 | -0.49 | -0.46 |
| Average Basic Shares Outstanding | 61.39M | 61.11M | 59.84M | 56.33M | 52.82M |
| Average Diluted Shares Outstanding | 61.39M | 61.11M | 59.84M | 56.33M | 52.82M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |